Future prospective histopathological examinations with inclusion of additional criteria and specific focus on phosphorylated FAK are warranted to determine a prognostic as well as a predictive biomarker signature that can reliably be used to individually select HNSCC patients for therapy. This evidence concerns the gene PTK2 and head and neck squamous cell carcinoma.